头孢匹林 | 515880-75-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 中文名称: 头孢匹林
• 英文名称: DMH4
• 英文别名: 4-(2-(4-(3-phenylpyrazolo[1,5-a]pyrimidin-6-yl)phenoxy)ethyl)morpholine；4-[2-[4-(3-Phenylpyrazolo[1,5-a]pyrimidin-6-yl)phenoxy]ethyl]morpholine
• CAS: 515880-75-8
• 化学式: C₂₄H₂₄N₄O₂
• 分子量: 400.48
• InChiKey: SKZQZGSPYYHTQG-UHFFFAOYSA-N

物化性质

• 密度：
  1.25±0.1 g/cm3(Predicted)
• 溶解度：
  DMSO：可溶，20mg/mL

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  30
• 可旋转键数：
  6
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  51.9
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  3-氨基-4-苯基-1H-吡唑 在 2,4,6-三甲基吡啶 、 caesium carbonate 、 溶剂黄146 、 sodium iodide 、 lithium iodide 作用下， 以 乙醇 、 N,N-二甲基甲酰胺 为溶剂， 生成 头孢匹林
  参考文献：
  名称：

  Optimization of a pyrazolo[1,5-a]pyrimidine class of KDR kinase inhibitors: improvements in physical properties enhance cellular activity and pharmacokinetics

  摘要：

  We have introduced solubilizing functionality to a 3,6-disubstituted pyrazolo[1,5-a]pyrimidine series of KDR kinase inhibitors to improve the physical properties of these compounds. The addition of a basic side-chain to the 6-aryl ring, introduction of 3-pyridyl groups, and most significantly, incorporation of a 4-pyridinonyl substituent at the 6-position of the core are modifications that maintain and often enhance the intrinsic potency of this class of inhibitors. Moreover, the improvements in physical properties result in marked increases in cellular activity and more favorable pharmacokinetics in rats. The synthesis and SAR of these compounds are described.(C) 2002 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(02)00827-2

文献信息

• The rational design of a novel potent analogue of the 5′-AMP-activated protein kinase inhibitor compound C with improved selectivity and cellular activity
  作者：Fouzia Machrouhi、Nouara Ouhamou、Keith Laderoute、Joy Calaoagan、Marina Bukhtiyarova、Paula J. Ehrlich、Anthony E. Klon

  DOI：10.1016/j.bmcl.2010.09.088

  日期：2010.11

  analogues of compound C, a non-specific inhibitor of 5′-AMP-activated protein kinase (AMPK), using a computational fragment-based drug design (FBDD) approach. Synthesizing only twenty-seven analogues yielded a compound that was equipotent to compound C in the inhibition of the human AMPK (hAMPK) α2 subunit in the heterotrimeric complex in vitro, exhibited significantly improved selectivity against a subset

  我们使用基于计算片段的药物设计 (FBDD) 方法设计并合成了化合物 C 的类似物，这是一种 5'-AMP 活化蛋白激酶 (AMPK) 的非特异性抑制剂。仅合成 27 种类似物就产生了一种化合物，该化合物在体外抑制异源三聚体复合物中的人 AMPK (hAMPK) α2 亚基方面与化合物 C 等效，对相关激酶子集的选择性显着提高，并显示出增强的细胞抑制AMPK。
• US8822684B1
  申请人：——

  公开号：US8822684B1

  公开（公告）日：2014-09-02
• US9040694B1
  申请人：——

  公开号：US9040694B1

  公开（公告）日：2015-05-26
• [EN] METHOD FOR PRODUCING MOTOR NEURONS FROM PLURIPOTENT CELLS<br/>[FR] PROCÉDÉ DE PRODUCTION DE NEURONES MOTEURS À PARTIR DE CELLULES PLURIPOTENTES
  申请人：INST NAT SANTE RECH MED

  公开号：WO2016012570A1

  公开（公告）日：2016-01-28

  The present invention concerns a method for producing a population of motor neuron progenitors comprising the following steps: a) culturing neuralized pluripotent cells in a culture medium C1 comprising an activator of the Wnt signaling pathway during a period of time T1 and b) culturing said cells in a culture medium C2 comprising retinoic acid and an agonist of the Hedgehog signaling pathway during a period of time T2.
• [EN] EFFICIENT AND RAPID SPECIFICATION OF SPINAL NEURONAL SUBTYPES FROM HUMAN PLURIPOTENT STEM CELLS<br/>[FR] SPÉCIFICATION EFFICACE ET RAPIDE DE SOUS-TYPES NEURONAUX RACHIDIENS À PARTIR DE CELLULES SOUCHES PLURIPOTENTES HUMAINES
  申请人：[en]INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE)

  公开号：WO2022112809A1

  公开（公告）日：2022-06-02

  The present invention relates to the targeted engineering of specific cell populations. Motoneurons (MN) subtypes display differential vulnerabilities in diseases and in spinal injuries. Engineered MNs of specific rostro-caudal identity represent an important resource for cell therapy approaches. However, these strategies remain impeded by slow and inefficient targeted differentiations due to the imprecise control over cell fate specificationin vitro. The inventors now used an embryoid body-based differentiation of hPSC and showed that the HOX clock expression can be controlled to generate subtypes of spinal MNs. Thus, the present invention relates to anin vitroor anex vivomethod for producing spinal neuronal subtypes comprising exposing axial progenitors to retinoic acid (RA), an agonist of Hedgehog signalling pathway, and optionally a FGFR agonist and/or an activator of the TGF pathway, wherein more and more caudal motor neurons identities are obtained by delayed exposure to RA and/or by exposure to RA in combination with the FGFR agonist and/or the activator of the TGF pathway.